Treatment of acute and chronic lymphoid leukaemia
Pharmacists should be able to describe the differences between acute lymphoblastic and chronic lymphocytic leukaemia and the available treatment.
Source: PR. J. Bernard / CNRI / Science Photo Library
Acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) are haematological malignancies that arise from the clonal proliferation of blood cells of the lymphoid lineage. Despite this element of commonality, the two diseases are markedly different in terms of presentation, natural history and treatment. In both diseases, there have been significant developments in drug treatments over the past two decades (see Figure 1), which will be discussed in this article.
Figure 1: Timeline of European Medicines Authority approval dates for treatment for acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL)
Acute lymphoblastic leukaemia
ALL is the most common cancer in children, with around 400 new cases of childhood leukaemia in the UK each year — 75% of these are ALL. It can affect children of any age, but is most often seen in children aged between one and four years old.
In adults, ALL is much less common, with an annual incidence of around 1 per 100,000 people; however, a similar total number of new diagnoses are seen in the paediatric setting each year.
The exact cause of ALL is unknown, although there are certain risk factors that mean some patients are more at risk than others. For example, children with certain genetic disorders, such as Down’s syndrome (DS), are known to have a higher risk of developing leukaemias. In 2018, it was proposed that development of ALL in children is a two-stage process: an in utero, genetic mutation leads to the development of a pre-leukaemic clone; and a second, postnatal genetic change — putatively triggered by infection — leads to the development of the observable disease.
Presentation and diagnosis
As leukaemia cells multiply in the bone marrow, the production of normal blood cells is reduced. The presenting symptoms arise from this and often include:
- Fatigue and pallor, owing to anaemia and low haemoglobin;
- Easy bruising, petechiae (appearing as a purple rash, owing to bleeding under the skin), and unusual bleeding (which may be slow to stop owing to reduced platelet numbers in blood);
- Frequent infections owing to a low number of normal white blood cells.
A blood test and examination of a blood film usually shows a low number of normal white blood cells and the presence of abnormal leukaemia cells, referred to as blasts. Examination of a bone marrow sample will confirm the diagnosis.
A sample of the bone marrow is usually taken from a bone at the rear of the hip using a specialised needle and is sent for cytogenetic analysis to look for any abnormal chromosomes and to detect minimal residual disease (MRD). This involves DNA technology and enables leukaemia to be detected below the level that can be seen by looking at the bone marrow under the microscope. Specific recommendations relating to the diagnostic work-up for adult ALL can be found in the latest European Society of Medical Oncologyguidelines on this topic.
The five-year survival rate for adults in the UK diagnosed with ALL is currently 35–40% and is particularly poor in older patients (<15% in patients aged over 65 years).
- Age at diagnosis — infants aged under one year are excluded from the standard paediatric protocols and receive a different, more intensified treatment protocol;
- Sex — trials showed that boys did less well than girls; therefore, boys now receive an extra year of maintenance chemotherapy;
- Presenting white cell count — children with a high white cell count have an inferior prognosis;
- Cytogenetics — non-random chromosomal alterations are seen in children at diagnosis. Some of these chromosome changes are associated with a good prognosis and some with an inferior prognosis. For example, Philadelphia chromosome-positive (Ph +) ALL has a poorer prognosis and is treated on a separate, more intensive treatment schedule;
- Response to treatment — bone marrow morphological examination and molecular quantification of residual leukaemia (MRD assessment) are used to assess response during and at the end of the first month of treatment,.
Overview of treatment
Treatment is risk-directed, meaning that children with a poorer prognosis receive more intensive treatment, while those with a good prognosis receive less intensive treatment. The aim is to not overtreat children who have a good prognosis and risk unnecessary treatment toxicity, but equally not to under-treat children who have an inferior prognosis and must not receive inadequate treatment.
In general, protocols for children and young adults involve patients being assigned to a three- or four-drug remission induction schedule, known as schedules A and B, respectively,. The schedule selected depends on the patient’s test results at diagnosis, age and white cell count. Patients who have a slow response to schedule A or B, or those who have other adverse features (e.g. high-risk cytogenetics) receive an intensified treatment, known as schedule C, after the first four weeks of treatment.
In general, schedules A, B and C all include remission induction therapy (i.e. to kill the leukaemia cells in the bone marrow), consolidation therapy (i.e. treatment to stop ALL from recurring), interim maintenance therapy, delayed intensification and maintenance therapy (i.e. to keep ALL away in the long term).
In children, the total treatment duration is just over two years for girls and three years for boys. The treatment of adult ALL follows a similar pathway, although the total duration of maintenance therapy is two years and is not sex-dependent.
The medicines given during remission induction are as follows:
- Vincristine — this is given intravenously, once per week for five weeks;
- Dexamethasone — this is a steroid with an antileukaemic action, given daily, usually orally;
- Pegaspargase — this is given by intramuscular injection in the first and the third week of treatment;
- Daunorubicin — this is given once a week via a central line during induction for schedule B patients or those switching to schedule C after the day-15 bone marrow test,,.
An important exception is in children with DS, who are at greater risk of sepsis than non-DS patients. For this reason, all patients with DS receive the same three-drug induction (schedule A) and no daunorubicin.
In the paediatric setting, all medicines will be given in (or supplied from, in the case of oral agents) designated centres specialising in the care of children with malignant disease.
Other medicines are given during the consolidation and maintenance stages of treatment, but it is beyond the scope of this article to detail the entire plan. More information can be found on the Cancer Research UK website..
Other treatment strategies
Allogenic haematopoietic stem cell transplant (HSCT) is an alternative treatment option for patients:
- Who do not respond to chemotherapy;
- With high-risk disease (e.g. Ph + ALL);
- With relapsed ALL.
However, owing to the improvements made in the treatment of childhood ALL, most children will not need to proceed to HSCT as part of their disease management.
For patients who require HSCT, it is usually more successful if the donor has the same tissue type as the patient. In adult ALL, the current Medical Research Council ‘UKALL14’ trial recommends that all patients with a sibling donor who achieve a complete response to induction chemotherapy proceed to allograft. However, patients without a sibling donor proceed to a matched unrelated donor transplant only if they are classified as high risk, which is based on presenting characteristics, cytogenetics (e.g. Ph + ALL) and their MRD status.
New developments in treatment
There are two National Institute for Health and Care Excellence (NICE)-approved immunotherapy agents for the treatment of relapsed or refractory B-cell ALL,. The choice of agent depends on which antigens are expressed by the leukaemia cell.
Blinatumomab is a bi-specific T-cell engager antibody that targets the CD3 protein on T-cells and the protein CD19 on the tumour cell. Whereas, inotuzumab ozogamicin is a conjugate of an anti-CD22 monoclonal antibody and a conventional cytotoxic agent.
NICE has also recently approved the use of blinatumomab for adult patients who achieve remission but have MRD activity,. Data suggest that both drugs increase the time patients have without their disease relapsing and, therefore, the drugs may be used as a ‘bridge’ to HSCT or to the other significant new therapy, chimeric antigen receptor (CAR-T) therapy.
In CAR-T therapy, the patient’s own T cells are removed and genetically modified so that they attach to and destroy leukaemia cells when they are given back to the patient by infusion. NICE has recently approved tisagenlecleucel, a form of CAR-T therapy that targets CD19, for the treatment of relapsed or refractory B-cell ALL in children and young adults aged up to 25 years. Very encouraging clinical results have been reported with this novel approach, although it presents several logistical and economic challenges to the NHS. For example, only selected centres in the UK are commissioned to deliver CAR-T therapy and, at the time of writing, there was not a formal way to record outcomes.
These novel therapies may change the landscape of both childhood and adult ALL treatment in the next few years and there is much for pharmacists to consider in ensuring the safe delivery of these relatively new treatments to patients. For example, how to ensure that their governance is in-line with the safe and secure handling of medicines.
Ongoing clinical trials
In the UK, a series of clinical trials have enabled the risk-directed approach to be taken forwards in the paediatric and young adult setting. For example, ‘UKALL 2011’, a phase III randomised controlled trial, recruited children and young people between the ages of 1 and 25 years with ALL from April 2012 to December 2018. The trial assessed whether changing the standard treatment for this patient group would reduce the side effects and help prevent the disease returning. Data analysis is currently ongoing.
Furthermore, the current UK-wide national phase III randomised controlled trial in adult ALL (UKALL14) is investigating the benefits of adding novel agents (rituximab in B-cell ALL and nelarabine in T-cell ALL) to the standard induction chemotherapy schedule. Patient recruitment ends in December 2020 and the trial is expected to end in 2022.
Chronic lymphocytic leukaemia
CLL is the most common leukaemia in adults in Western countries, with an age-adjusted UK incidence of 6 cases per 100,000 people per year. It accounts for around 1% of all new cancer cases in the UK and the median age at diagnosis is 72 years. The disease is more common in men, with a male to female ratio of 1.7:1 and there is evidence of a familial predisposition, with family members of patients with CLL having between a 6 to 9-fold increased risk of developing the disease,.
The exact cause of CLL is unclear, but the increased familial risk of developing the disease suggests that an inherited genetic change may be involved.
Presentation and diagnosis
In most cases, patients are asymptomatic and the disease is detected incidentally during a routine blood test. Symptoms, if present, may include lymphadenopathy, recurrent infections, fever, night sweats and weight loss. Cytopenias may also be seen, owing to infiltration of the bone marrow.
A diagnosis of CLL requires the presence of ≥5x109/L clonal B-lymphocytes in the peripheral blood for at least three months. Immunophenotyping, using flow cytometry, is necessary to confirm the clonality of the population. If the clonal population is smaller (i.e. <5x109/L) and the patient is asymptomatic, then the condition is designated as monoclonal B-lymphocytosis (MBL).
This can be considered a pre-malignant condition and requires close follow-up because each year 1–2% of patients with MBL will go on to develop CLL. Characteristic immunophenotypic features of CLL (e.g. high expression of CD5, CD23 and CD43, and low level expression of CD20 and CD79B) help to distinguish CLL from other conditions, such as mantle cell lymphoma, lymphoplasmocytic lymphoma and marginal zone lymphoma,.
CLL is staged by either the Binet or the Rai system; the former is more widely used in Europe (see Table 1), while the latter is preferred in the United States,. Both systems divide patients into three groups based on physical symptoms and blood counts.
|Table 1: Binet staging system for chronic lymphocytic leukaemia, using the five lymph node regions — cervical, axillary, inguinal, spleen and liver|
Less than three impacted lymph node regions
Less than three impacted lymph node regions
|C||Haemoglobin <100g/L or platelets <100x109/L||6.5 years|
|Adapted from Ann Oncol; Blood|
CLL is generally considered an incurable condition, although, as can be seen from Table 1, many patients will live for between five to ten years after diagnosis. As well as clinical stage, patient age and serum β-microglobulin concentrations have also been shown to influence prognosis. As with many other malignancies, cytogenetic analysis (i.e. assessing an individual’s entire genome) is increasingly used to assist in predicting outcome and determining optimal treatment.
A number of abnormalities (e.g. deletion 17p, deletion 11q and mutated TP53) are associated with a poorer outcome, while others (e.g. mutated immunoglobulin heavy chain variable) appear to confer a more favourable prognosis. Around 5–10% of patients will be found to have TP53 disruption (either deletion 17p or mutated TP53) at diagnosis. Given that TP53 is a major tumour suppression gene, it is not surprising that these patients have been shown to have a poor prognosis and, as discussed in more detail below, usually require a different type of drug treatment to control their disease.
Overview of treatment
Not all patients will require immediate treatment after receiving a diagnosis of CLL. Asymptomatic patients with early-stage disease are currently managed with a “watch and wait” approach because there is no evidence to support the use of chemotherapy in this subpopulation,. However, recent data demonstrating a marked improvement in event-free survival with ibrutinib in asymptomatic patients who were determined to be at increased risk of progression, may lead to a re-evaluation of this position.
In 2018, the International Workshop on Chronic Lymphocytic Leukemia updated their treatment initiation guidance and their current criteria for starting treatment are summarised in the Box.
Box: International Workshop on Chronic Lymphocytic Leukemia criteria for initiating chronic lymphocytic leukaemia treatment
Active disease should be clearly documented before therapy is initiated. At least one of the following criteria should be met:
- Evidence of progressive marrow failure as manifested by the development, or worsening, of anaemia (haemoglobin <100g/L) and/or thrombocytopaenia (platelets <100x109/L);
- Splenomegaly that is massive (i.e. ≥6cm below the left costal margin), progressive or symptomatic;
- Lymphadenopathy with massive nodes (i.e. ≥10cm in longest diameter) or that is progressive or symptomatic;
- Progressive lymphocytosis with an increase of 50% or more over a two-month period, or a lymphocyte doubling time of less than six months. Factors contributing to lymphocytosis other than chronic lymphocytic leukaemia (e.g. infections or steroid administration) should be excluded;
- Autoimmune complications including anaemia or thrombocytopaenia poorly responsive to corticosteroids;
- Symptomatic or functional extranodal involvement (e.g. skin, kidney, lung or spine);
- Disease-related symptoms as defined by any of the following:
- Unintentional weight loss of 10% or more within the previous six months;
- Significant fatigue (i.e. Eastern Cooperative Oncology Group performance scale ≥2);
- Fevers (i.e. of 38.0°C or more) for two or more weeks without evidence of infection;
- Night sweats for one month or more without evidence of infection.
From a UK perspective, choice of treatment is primarily influenced by current NICE guidance,,,,,,. However, where there is more than one option available for a given patient, treatment decisions should be guided by the side-effect profile of individual agents, taking into consideration patient fitness and the presence of comorbidities. Treatment must also be stratified on the basis of the results of molecular genetic testing. This is because chemoimmunotherapy has been shown to have poor efficacy in patients with a TP53 mutation or 17p deletion and, therefore, it should not be offered to this subgroup of patients,. Novel oral drugs that target the B-cell receptor signalling pathways (e.g. ibrutinib, idelalisib) or the anti-apoptotic protein B-cell lymphoma 2 (BCL -2; e.g. venetoclax) have demonstrated impressive response rates in phase III clinical trials and are increasingly being used in these patients,,.
In patients with an intact TP53 pathway, chemoimmunotherapy is considered an appropriate choice. Based on the pivotal CLL8 trial, the combination of fludarabine, cyclophosphamide and rituximab (FCR) is regarded as the standard of care in fitter patients,. In patients for whom fludarabine -based chemotherapy is deemed unsuitable (e.g. patients with renal impairment or older patients), the combination of rituximab plus bendamustine (BR) is a potential option.
Although the progression-free survival (PFS) in the CLL10 trial of FCR versus BR was lower with BR (42 months vs. 55 months), tolerability — particularly in relation to severe neutropenia and infection — was significantly better. Frailer patients should receive chlorambucil, either alone or in combination with an anti-CD20 monoclonal antibody. In the UK, this is usually obinutuzumab, although it should be noted that the greater efficacy of obinutuzumab comes at the expense of a higher rate of grade 3–4 infusional toxicity (20% vs. 4%) when compared with rituximab.
A potential treatment pathway (based on current British Society for Haematology and NICE guidance) for first-line treatment of CLL is summarised in Figure 2,. However, it must be emphasised that treatment options will vary depending on the geographical setting. For example, in the United States, ibrutinib is widely recommended as a first-line treatment in all patient groups, both with and without TP53 aberrations. Furthermore, the recent publication of impressive data for a number of novel combinations including ibrutinib plus venetoclax, ibrutinb plus obintuzumab and obinutuzumab plus venetoclax in the first-line setting means the treatment algorithm will likely continue to evolve,,.
Figure 2: First line treatment options for chronic lymphocytic leukaemia
Source: National Institute for Health and Care Excellence; Br J Haem
In patients with relapsed or refractory CLL, treatment choices will be influenced by patient age, comorbidities and TP53 status, as well as the extent, tolerability and duration of response to first-line treatment. Current options include chemoimmunotherapy, ibrutinib, idelalisib plus rituximab and venetoclax (either alone or in combination with rituximab),.
This oral agent targets Bruton tyrosine kinase (BTK), an important molecule in the B-cell receptor signalling pathway that drives cell proliferation. It is taken on a continuous basis at a dose of 420mg once daily and has demonstrated impressive efficacy in both the first-line and relapsed CLL setting, and in patients with or without TP53 deletion or mutation,,. For example, recently published extended follow-up data from the pivotal RESONATE study — which compared ibrutinib with ofatumumab in patients with relapsed CLL — demonstrated a 91% overall response rate for the ibrutinib arm and a significant benefit over ofatumumab in terms of both PFS and overall survival.
The tolerability profile of ibrutinib, as with other targeted therapies, is somewhat different to that seen with conventional chemotherapy. Specific adverse effects to be aware of include diarrhoea, bleeding (inhibition of BTK has been shown to interfere with platelet aggregation), atrial fibrillation (three-fold increase in risk reported), hypertension, arthralgia/myalgia and an increased susceptibility to infection. Marked lymphocytosis is often seen during the first few months of ibrutinib therapy, owing to tumour cells moving from the lymph nodes into the peripheral circulation. It is important that an increase in lymphocyte count is not taken as a sign of progressive disease but rather as an expected on-target effect of the ibrutinib.
Pharmacists need to be aware that ibrutinib is hepatically metabolised, primarily via CYP3A4, so it should be avoided, if possible, in patients who are taking strong CYP3A4 inducers (e.g. phenytoin, rifampicin) or inhibitors (e.g. clarithromycin, posaconazole). A careful medication review must be undertaken prior to starting ibrutinib, and patients should also be counselled about avoiding grapefruit and Seville oranges because they are predicted to increase exposure to ibrutinib.
This is an oral inhibitor of phosphatidylinositol -3-kinase, an intracellular tyrosine kinase that is also an important driver of B-cell proliferation via its effect on various signalling pathways. Idelalisib is given at a dose of 150mg twice daily, usually in combination with rituximab. Strong efficacy data in both the first-line and relapsed setting led to NICE approval,. However, a subsequent analysis of clinical trial data demonstrated an increased rate of infection and death, therefore, its license was modified and it is now recommended that first-line use should be restricted to patients with TP53 disruption who are not eligible for any other therapy. In light of this safety review, Pneumocystis jiroveci pneumonia (PJP) prophylaxis and regular monitoring for cytomegalovirus (CMV) infection are now recommended. Concern has also been raised in relation to idelalisib- induced hepatotoxicity, possibly immune-mediated, and it is advised to monitor patients’ transaminases and total bilirubin every two weeks for the first three months of treatment. Idelalisib is both metabolised by CYP3A and its primary metabolite is a strong CYP3A inhibitor so, as with ibrutinib, potential drug–drug and drug–food interactions need to be considered.
This is the most recent addition to the treatments available of CLL,. It induces apoptosis by targeting the anti-apoptotic protein BCL2 that is known to be overexpressed in CLL cells. Venetoclax in combination with rituximab has recently been approved by NICE for use in the second-line setting, based on the results of the MURANO study of 389 patients that showed a marked difference in two-year PFS (85% vs. 36%, P<0.001) when compared with rituximab–bendamustine. Venetoclax can also be used as a single agent in relapsed disease and in the first-line setting for patients with a TP53 deletion or mutation who are not suitable for treatment with a B-cell receptor pathway inhibitor,.
Common side effects of venetoclax include neutropenia, tumour lysis syndrome (TLS) and infection. The risk of TLS is particularly high and a gradual dose escalation schedule (usually on an inpatient basis) must be followed for all patients starting treatment with this drug,(see Table 2). Importantly, strong CYP3A4 inhibitors (e.g. clarithromycin and voriconazole) are contraindicated in patients receiving venetoclax. In patients who are receiving moderate CYP3A4 inhibitors (e.g. ciprofloxacin and fluconazole), dose adjustment of the venetoclax is mandated.
|Table 2: Dose titration schedule for venetoclax|
|Source: Electronic Medicines Compendium|
|Week||Venetoclax daily dose (mg)|
Other treatment strategies
Allogeneic stem cell transplant is a potentially curative option that may be considered for younger, fitter patients with relapsed or refractory CLL,. Given the excellent results being seen with the novel targeted therapies in this disease, its future role is subject to ongoing debate. However, it remains the standard of care for CLL patients with Richter’s transformation who have obtained a remission with conventional chemotherapy.
Maintenance therapy is increasingly used in other haematological malignancies, such as myeloma and acute myeloid leukaemia. Although PFS benefits have been demonstrated for anti-CD20 monoclonal antibodies and lenalidomide maintenance in the CLL setting, concerns about the long-term tolerability and a lack of an overall survival benefit mean that this strategy is not routinely recommended,,,,.
In around 10% of patients with CLL, their disease will eventually transform to diffuse large B-cell lymphoma (DLBCL), a phenomenon called Richter’s transformation. Unfortunately, this usually has a poorer outcome than de novo DLBCL. Transformation to Hodgkin lymphoma is also seen, albeit rarely. Healthcare professionals should be aware that patients with CLL have a two- to seven-fold increased risk of developing a secondary malignancy (mostly solid cancers). Therefore, patients should be encouraged to participate in national screening programmes (e.g. bowel cancer screening programmes).
A reduction in humoral immunity is characteristic of CLL and this, taken alongside the myelosuppressive and immunosuppressive effect of treatment, means that patients are at increased risk of a variety of infectious complications. Most infections are bacterial but fungal, viral and opportunistic infections are also seen, necessitating careful monitoring and the use of prophylactic anti-infectives (e.g. co-trimoxazole and antivirals). Influenza and pneumococcal vaccinations are also recommended, and immunoglobulin replacement therapy should be considered in the setting of hypogammaglobulinaemia with recurrent infections.
Finally, autoimmune cytopaenias (most commonly autoimmune haemolytic anaemia or immune thrombocytopenic purpura) have been reported in up to 20% of patients with CLL.
For both ALL and CLL, patient outcomes continue to improve, partly driven by improved clinical trial design and partly through the introduction of a range of novel treatments, focusing on molecular or immunological targets. However, further progress is required, particularly in the setting of adult ALL where many patients will die of their disease within five years of diagnosis.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207486
Test your knowledge
Closing date: 21 January 2021
Required score to pass: 70%
Sign in to take this article's CPD module.
CPD modules and learning certificates are only available to RPS members and subscribers.Sign in here
Recommended from Pharmaceutical Press